Achaogen Inc (AKAO) : Wellcome Trust Ltd (the) As Trustee Of The Wellcome Trust has sold out all of its stake in Achaogen Inc during the most recent quarter, according to the disclosure filed by the company on Jul 21, 2016 with the SEC. The investment management company has sold out 1,125,616 shares of Achaogen Inc which is valued at $4,423,671.
Other Hedge Funds, Including , Acadian Asset Management boosted its stake in AKAO in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 328 shares of Achaogen Inc which is valued at $1,269. Simplex Trading sold out all of its stake in AKAO during the most recent quarter. The investment firm sold 185 shares of AKAO which is valued $716.Gierl Augustine Investment Management Inc boosted its stake in AKAO in the latest quarter, The investment management firm added 500 additional shares and now holds a total of 1,500 shares of Achaogen Inc which is valued at $5,535. Achaogen Inc makes up approx 0.01% of Gierl Augustine Investment Management Inc’s portfolio.Creative Planning boosted its stake in AKAO in the latest quarter, The investment management firm added 14,900 additional shares and now holds a total of 15,000 shares of Achaogen Inc which is valued at $55,350.Mazama Capital Management Inc reduced its stake in AKAO by selling 102,142 shares or 7.62% in the most recent quarter. The Hedge Fund company now holds 1,238,936 shares of AKAO which is valued at $4,757,514. Achaogen Inc makes up approx 0.93% of Mazama Capital Management Inc’s portfolio.
Achaogen Inc closed down -0.07 points or -1.75% at $3.92 with 44,278 shares getting traded on Thursday. Post opening the session at $4.02, the shares hit an intraday low of $3.87 and an intraday high of $4.02 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Many Wall Street Analysts have commented on Achaogen Inc. Company shares were Upgraded by Wedbush on Jun 14, 2016 to ” Outperform”, Firm has raised the Price Target to $ 10 from a previous price target of $7 .
Achaogen Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery development and commercialization of antibacterials to treat multidrug resistant (MDR) gram-negative infections. The Company’s lead product plazomicin is used to treat bacterial infections due to MDR enterobacteriaceae including carbapenem-resistant enterobacteriaceae (CRE) and is in Phase III Clinical trials. In addition to plazomicin the Company’s research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections. The first is a program to discover and develop small molecule inhibitors of LpxC which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria and the second is a therapeutic antibody program to generate mAbs (monoclonal antibodies) that can be deployed as a monotherapy to treat infections caused by MDR Acinetobacter baumannii and other gram-negative pathogens.